07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

Arteriocyte, U.S. Department of Health and Human Services dermatology news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Arteriocyte a contract worth up to $101.1 million to develop its Magellan Bio-Bandage to treat thermal burn injury. Arteriocyte will receive $11.8 million for an initial...
01:00 , Sep 28, 2013 |  BC Extra  |  Company News

BARDA awards up to $355.1M for countermeasures

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded biodefense contracts worth up to $355.1 million to four companies, including $194 million to increase the national stockpile of leukocyte growth factors for treatment of acute...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Clinical News

Magellan autologous platelet gel: Phase I start

Early this year, Arteriocyte will begin a U.S. Phase I trial to evaluate autologous platelet gel using Magellan Autologous Platelet Separator technology. The treatment was developed in partnership with the U.S. Telemedicine and Advanced Technology...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Company News

Arteriocyte gene/cell therapy news

Arteriocyte received a $283,861 grant from NIH's National Heart, Lung and Blood Institute to develop the company's Nanex stem cell culture and expansion technology for use in bone marrow transplants of ex vivo umbilical cord...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Clinical News

Magellan MAR01: Phase I started

Arteriocyte began an open-label, U.S. Phase I trial to evaluate Magellan MAR01 in an undisclosed number of patients who are not eligible for revascularization surgery. Arteriocyte Inc. , Cleveland, Ohio   Product: Magellan MAR01  ...
08:00 , Jan 23, 2006 |  BC Week In Review  |  Clinical News

Adult derived hemangioblasts: Phase I started

Arteriocyte started a U.S. Phase I trial in 10 patients who are not candidates for existing treatments such as angioplasty or stent replacement. Arteriocyte Inc. , Cleveland, Ohio   Product: Adult derived hemangioblasts   Business:...